{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:01:49Z","timestamp":1793980909242,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cllc.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:28:04Z","timestamp":1527312484000},"page":"e721-e734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical Characteristics and Prognosis of Patients With Advanced Non\u2013Small-cell Lung Cancer Who Are Ineligible for Clinical Trials"],"prefix":"10.1016","volume":"19","author":[{"given":"Hayato","family":"Kawachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3000","authenticated-orcid":false,"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.05.014_bib1","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1002\/1097-0142(19900515)65:10+<2376::AID-CNCR2820651504>3.0.CO;2-A","article-title":"National Cancer Institute sponsored cooperative clinical trials","volume":"65","author":"Friedman","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.05.014_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cllc.2018.05.014_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncr.22436","article-title":"Provider roles in the recruitment of underrepresented populations to cancer clinical trials","volume":"109","author":"Howerton","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.05.014_bib6","series-title":"Clinical Trials: Design, Conduct, and Analysis","author":"Meinert","year":"2009"},{"key":"10.1016\/j.cllc.2018.05.014_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0895-4356(97)00240-0","article-title":"A\u00a0study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group","volume":"51","author":"Fuks","year":"1998","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cllc.2018.05.014_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JOP.2013.001119","article-title":"The National Cancer Institute-American Society of Clinical Oncology cancer trial accrual symposium: summary and recommendations","volume":"9","author":"Denicoff","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.cllc.2018.05.014_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JTO.0b013e3181fb50d8","article-title":"Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-9-130","article-title":"Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials","volume":"9","author":"Vardy","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2018.05.014_bib11","unstructured":"Al-Baimani K, Jonker H, Zhang T, et\u00a0al. Are clinical trial eligibility criteria an accurate reflection of a real world population of advanced lung cancer patients? Presented at the World Conference on Lung Cancer; September 6-9, 2015; Denver, CO (abstract 1398)."},{"key":"10.1016\/j.cllc.2018.05.014_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2001.19.6.1728","article-title":"Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment","volume":"19","author":"Lara","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib13","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2018.05.014_bib14","series-title":"International Union Against Cancer. TNM Classification of Malignant Tumours","author":"Sobin","year":"2010"},{"key":"10.1016\/j.cllc.2018.05.014_bib15","author":"US National Institutes of Health"},{"key":"10.1016\/j.cllc.2018.05.014_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/resp.12661","article-title":"Impact of COPD and emphysema on survival of patients with lung cancer: a meta-analysis of observational studies","volume":"21","author":"Gao","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.cllc.2018.05.014_bib17","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00432-016-2199-z","article-title":"Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival","volume":"142","author":"Kanaji","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3892\/ol.2012.753","article-title":"Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia","volume":"4","author":"Kinoshita","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cllc.2018.05.014_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ejrad.2015.01.021","article-title":"Interstitial lung abnormalities in treatment-na\u00efve advanced non-small-cell lung cancer patients are associated with shorter survival","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cllc.2018.05.014_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mds344","article-title":"Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study","volume":"24","author":"Janus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.05.014_bib22","first-page":"106","article-title":"Impact of prior cancer on eligibility for lung cancer clinical trials","author":"Gerber","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2018.05.014_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ejcts.2008.08.004","article-title":"Multiple independent primary cancers do not adversely affect survival of the lung cancer patient","volume":"34","author":"Aguil\u00f3","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2018.05.014_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-5002(00)00208-7","article-title":"The prognostic significance of a previous malignancy in operable non-small cell lung cancer","volume":"32","author":"Koppe","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.05.014_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1185\/03007995.2013.816276","article-title":"Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review","volume":"29","author":"Nandy","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cllc.2018.05.014_bib26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1634\/theoncologist.2011-0214","article-title":"Second malignancies among elderly survivors of cancer","volume":"16","author":"VanderWalde","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.05.014_bib27","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-06-0414","article-title":"The epidemiology of second primary cancers","volume":"15","author":"Travis","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cllc.2018.05.014_bib28","first-page":"107","article-title":"Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual","author":"Laccetti","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2018.05.014_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2016.05.029","article-title":"Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-Medicare analysis","volume":"98","author":"Laccetti","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.05.014_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1548-5315(11)70546-0","article-title":"Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists","volume":"6","author":"Fenton","year":"2009","journal-title":"Commun Oncol"},{"key":"10.1016\/j.cllc.2018.05.014_bib31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/annonc\/mdv619","article-title":"Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real word: a systematic review and meta-analysis","volume":"27","author":"Truong","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:55Z","timestamp":1761505735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418301347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525730418301347"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.05.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics and Prognosis of Patients With Advanced Non\u2013Small-cell Lung Cancer Who Are Ineligible for Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}